Alaunos Therapeutics, Inc. (TCRT)

NCM – Real Time Price. Currency in USD

2.08

+0.01 (0.48%)

At close: Jun 26, 2026, 4:00 PM EDT

2.41

+0.33 (15.87%)

After-hours: Jun 26, 2026, 7:38 PM EDT

26.05.2026

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders.

18.05.2026

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.

04.05.2026

Valion Bio Appoints Melinda Lackey as General Counsel

Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth.

02.03.2026

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.

02.03.2026

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.

Videos

No Data

There is no data to display

Press releases

26.05.2026

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

18.05.2026

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

04.05.2026

Valion Bio Appoints Melinda Lackey as General Counsel

02.03.2026

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.

Alaunos Therapeutics, Inc. (TCRT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alaunos Therapeutics, Inc. (TCRT)

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Videos

No Data

Press releases

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Videos

No Data

Press releases

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Search stocks

Alaunos Therapeutics, Inc. (TCRT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alaunos Therapeutics, Inc. (TCRT)

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Videos

No Data

Press releases

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Videos

No Data

Press releases

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

Valion Bio Appoints Melinda Lackey as General Counsel

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders